Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment

Merja Kokki, Moona Kuronen, Toivo Naaranlahti, Timo Nyyssönen, Ira Pikkarainen, Sakari Savolainen, Hannu Kokki, Merja Kokki, Moona Kuronen, Toivo Naaranlahti, Timo Nyyssönen, Ira Pikkarainen, Sakari Savolainen, Hannu Kokki

Abstract

Introduction: Opioids are needed for postoperative pain in spine surgery patients, but opioid-induced constipation is a harmful adverse event. The aim of this clinical trial was to compare the use of a controlled-release oxycodone-naloxone combination product with oxycodone controlled-release tablets in these patients. The main outcome measure was the prevalence of constipation at 7 days postoperatively assessed with a Bowel Function Index questionnaire. A follow-up assessment at 21 days after surgery was also included.

Methods: A total of 180 patients undergoing spine surgery, 91 having preoperative opioids in use and 89 opioid-naïve, were randomized to receive twice-daily oxycodone 10 mg or oxycodone-naloxone 10/5 mg controlled-release tablets for the first 7 postoperative days. Patients were followed-up for 21 days after surgery.

Results: At baseline, prevalence of constipation was common both in the opioid-naïve-25/87 (29%) and on-opioid groups 43/90 (48%) (P = 0.009). This increased at 7 days postoperatively with no difference between the groups, 54/89 with oxycodone and 54/88 with oxycodone-naloxone had constipation. At 21 days, constipation was less than in the baseline in both groups, in the opioid-naïve group the prevalence of constipation was 3/43 (7%) in patients with oxycodone-naloxone compared to 9/44 (21%) with oxycodone (effect size 0.68; P = 0.068). Both study compounds provided similar pain relief and were well tolerated.

Conclusion: In patients presented for back surgery, the prevalence of constipation was significantly higher than that in the community. In opioid-naïve subjects, oxycodone-naloxone was beneficial concerning constipation; but this was not distinguishable in subjects with chronic opioid use. The analgesic efficacy of oxycodone and oxycodone-naloxone was similar.

Trial registration: European Clinical Trials Database (EudraCT no. 2012-001816-42) and ClinicalTrials.gov database (Identifier: NCT02573922).

Keywords: Constipation; Opioid induced bowel dysfunction (OIC); Oxycodone; Oxycodone-naloxone; Spine surgery.

Figures

Fig. 1
Fig. 1
Flow chart

References

    1. Gerbershagen H, Aduckathil S, van Wijck A, Peelen L, Kalkman C, Meissner W. Pain intensity on the first day after surgery: a prospective cohort study comparing 179 surgical procedures. Anesthesiology. 2013;118:934–944. doi: 10.1097/ALN.0b013e31828866b3.
    1. Kalso E, Edwards J, Moore R, McQuay H. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112:372–380. doi: 10.1016/j.pain.2004.09.019.
    1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182:11–18. doi: 10.1016/S0002-9610(01)00782-6.
    1. Portenoy R. Constipation in the cancer patient: causes and management. Med Clin N Am. 1987;71:303–311. doi: 10.1016/S0025-7125(16)30872-0.
    1. Bell T, Panchal S, Miaskowski C, Bolge S, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1) Pain Med. 2009;10:35–42. doi: 10.1111/j.1526-4637.2008.00495.x.
    1. Pizzi L, Toner R, Foley K, et al. Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery. Pharmacotherapy. 2012;32:502–514. doi: 10.1002/j.1875-9114.2012.01101.x.
    1. The Report of the International Narcotics Control Board for 2015 (E/INCB/2015/1), United Nations. . Accessed 21 Oct 2016.
    1. Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain. 2009;13:954–962. doi: 10.1016/j.ejpain.2008.11.006.
    1. Kokki H, Kokki M, Sjövall S. Oxycodone for the treatment of post-operative pain. Expert Opin On Pharmacother. 2012;13:1045–1058. doi: 10.1517/14656566.2012.677823.
    1. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Therap. 2012;50:360–367. doi: 10.5414/CP201646.
    1. Kokki M, Välitalo P, Rasanen I, et al. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy. Eur J Clin Pharmacol. 2012;68:1357–1363. doi: 10.1007/s00228-012-1267-9.
    1. Rothwell M, Pearson D, Hunter J, et al. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study. Br J Anaesth. 2011;106:865–872. doi: 10.1093/bja/aer084.
    1. Kuusniemi K, Zöllner J, Sjövall S, et al. Prolonged-release oxycodone/naloxone in postoperative pain management: from a randomized clinical trial to usual clinical practice. J Int Med Res. 2012;40:1775–1793. doi: 10.1177/030006051204000516.
    1. Comelon M, Wisloeff-Aase K, Raeder J, et al. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy. Acta Anaesthesiol Scand. 2013;57:509–517. doi: 10.1111/aas.12051.
    1. Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015;23:823–830. doi: 10.1007/s00520-014-2435-5.
    1. Rentz A, Yu R, Müller-Lissner S, Leyendecker P. Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation. J Med Econ. 2009;12:371–383. doi: 10.3111/13696990903430481.
    1. Helakorpi S, Pajunen T, Jallinoja P, Virtanen S, Uutela A. Health behaviour and health among the Finnish adult population, Spring 2010. National Institute for Health and Welfare (THL), Report 15/2011, 203 pages. Helsinki 2011. ISBN 978-952-245-472-0 (print), ISBN 978-952-245-473-7 (pdf). . Accessed 15 Aug 2016.
    1. Suares N, Ford A. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:1582–1591. doi: 10.1038/ajg.2011.164.
    1. Usubiaga JE, Moya F, Usubiaga LE. Effect of thoracic and abdominal pressure changes on the epidural space pressure. Br J Anaesth. 1967;39:612–618. doi: 10.1093/bja/39.8.612.
    1. Brock C, Olesen S, Olesen A, Frøkjaer JB, Andresen T, Drewes A. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs. 2012;72:1847–1865. doi: 10.2165/11634970-000000000-00000.
    1. Stienen M, Smoll N, Hildebrandt G, Schaller K, Tessitore E. Gautschi. Constipation after thoraco-lumbar fusion surgery. Clin Neurol Neurosurg. 2014;126:137–142. doi: 10.1016/j.clineuro.2014.08.036.
    1. Planas E, Poveda R, Sánchez S, Romero A, Puig M. Non-steroidal anti-inflammatory drugs antagonise the constipating effects of tramadol. Eur J Pharmacol. 2003;482:223–226. doi: 10.1016/j.ejphar.2003.09.048.
    1. Summary of product characteristics Lyrica. . Accessed 15 Aug 2016.
    1. Summary of product characteristics Neurontin. . Accessed 15 Aug 2016.
    1. Coyne K, LoCasale R, Datto C, Sexton C, Yeomans K, Tack J. Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Clinicoecon Outcomes Res. 2014;6:269–281. doi: 10.2147/CEOR.S61602.
    1. Poelaert J, Koopmans-Klein G, Dioh A, et al. Treatment with prolonged-release oxycodone/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation. Clin Ther. 2015;37:784–792. doi: 10.1016/j.clinthera.2015.02.010.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel